BANNOCKBURN, Ill.--(BUSINESS WIRE)--Option Care Enterprises, Inc., one of the nation’s leading providers of home and alternate treatment site infusion services, has been selected as a contracted provider of a new 20% formulation of subcutaneous immunoglobulin (SCIG) therapy for primary immunodeficiency (PI). CUVITRU™ [Immune Globulin Subcutaneous (Human), 20% Solution] is manufactured by Shire plc.
CUVITRU™ recently was approved by the U.S. Food and Drug Administration to treat adult and pediatric patients two years and older with PI, a group of more than 300 genetic disorders in which part of the body’s immune system is missing or functions improperly.
“Option Care has a proven track record of providing compassionate, high-quality clinical care in the home or at alternate treatment sites to patients undergoing therapy for a variety of complex conditions, including those with primary immunodeficiency,” said Lisa Betts, Vice President, Specialty Programs, Option Care. “As one of the largest national providers of immunoglobulin therapy, we are pleased to offer CUVITRU™ to support primary immunodeficiency patients as we continue to spread awareness and improve treatment options.”
Immunoglobulin (IG) is a lifelong therapy provided to prevent recurrent infections in patients with PI, which affects as many as six million people worldwide.
View the entire original article here at BusinessWire.com
The views, opinions and positions expressed within these guest posts are those of the author alone and do not represent those of Becker's Hospital Review/Becker's Healthcare. The accuracy, completeness and validity of any statements made within this article are not guaranteed. We accept no liability for any errors, omissions or representations. The copyright of this content belongs to the author and any liability with regards to infringement of intellectual property rights remains with them.